ADX bags $2.6M in quarterly sales as Austrian oil-gas output lifts 23%
The company has also flicked the switch on a gas-fuelled exploration blitz by launching plans for a multi-well, shallow drilling program in Upper Austria that could open the cash flow gates.
The ASX-listed explorer says total output lifted to 303 barrels of oil equivalent per day (BOEPD) for the past three months, up substantially from 246BOEPD in the March quarter.
Despite oil prices sliding 10 per cent for the period, the company was still able to eke out a 4 per cent improvement in revenue to €1.56 million (A$2.76 million).
Much of the production growth came from the company's Vienna Basin operations, which averaged 238BOEPD, up from 190BOEPD. The improved performance came after a five-well workover program lifted oil and gas production by 25 per cent and 47 per cent, respectively. The program to repair subsurface equipment and clean up holes was completed in March.
ADX also used the quarter to supercharge its gas credentials by hooking up a new carbon dioxide removal unit at its Vienna Basin operations, allowing it to meet strict CO₂ specs for grid operator Netz NÖ without relying on third-party blending.
The company says the move has boosted its commercial independence and could pave the way for even greater gas production down the track.
In the company's Upper Austrian leases, the Anshof-3 and Anshof-2A wells continued to perform, contributing 66 barrels of oil a day during the quarter compared to 56 barrels in the previous quarter.
Notably, the revenue line at the Anshof fields has benefited more from ADX's increased stake in the leases after ex-partner Xstate Resources relinquished its 20 per cent stake in exchange for forgiveness of €547,075 (A$971,000) in unpaid cash calls.
The move gave ADX 70 per cent of the broader production area and helped solidify its control of the nearby 3000-barrel-per-day capacity permanent production facility.
Directly north of the Anshof field, ADX has been busy locking up land covering two new prospects – dubbed Lind and SGB – seen as excellent appraisal and exploration opportunities. The company says that if these prospects eventually deliver the goods, production could be easily tied back into the processing plant at minimal cost.
At the same time, ADX has matured three new drill-ready shallow gas prospects in its ADX-AT-II licence area, including the GOLD prospect, which is on track to spud in late 2025 or early 2026.
The company says the GOLD, GRAB and ZAUN prospects offer combined mean prospective resources of 13 billion cubic feet (Bcf) and are near key gas infrastructure, boosting their development economics.
The trio of prospects form the first cluster of a broader campaign across seven shallow gas targets estimated to hold a total mean prospective resource of 29Bcf. A farmout process is already under way to support a multi-well drilling program.
Meanwhile, the company is gearing up to resume testing at its Welchau-1 oil discovery, pending court resolution of environmental objections. Ongoing work during the quarter defined two new follow-up leads – the deeper Welchau target and the Rossberg prospect to the north.
ADX is also preparing to firm up its new offshore Sicily Channel gas acreage. The final anti-corruption compliance hurdle has been cleared and the permit is now expected to be formally granted in the third quarter.
Results from historic wells and earlier seismic surveys from the Italian leases have pointed to the potential for sweet gas reservoirs and new data acquisition is being planned.
In addition to ramping up near-term production growth, ADX is also eyeing a transition to renewables. It has matured a solar project in the Vienna Basin with 5.4 megawatts capacity and is assessing hydrogen storage options in depleted fields.
With growing production, drill-ready gas targets and new acreage in play, ADX is well placed to tap rising European demand for clean, local energy sources.
Is your ASX-listed company doing something interesting? Contact:
matt.birney@wanews.com.au
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Dr Boreham's Crucible: Telix has homework but remains dux of radioimaging class
With multiple clinical trials and approval applications in train, nuclear medicine superstar Telix Pharmaceuticals (ASX:TLX) is like one of those irritatingly brilliant all-round students. We're thinking of the straight-A school captain who stars in the school play, whilst padding up for the First XI in between clarinet lessons. But when Goody Two Shoe's Latin grade slips to B+, panic ensues – mainly on the part of overbearing 'parents' (investors). Last month, Telix experienced the corporate version of such angst when it revealed the US Securities and Exchange Commission (SEC) had varied subpoenaed 'various documents and information'. These relate mainly to Telix's disclosures about its prostate cancer therapeutic program. While the company dubbed the entreaty a 'fact finding request', investors birched the stock by 15%. Telix has a nearer-term focus on winning US Food & Drug Administration (FDA) approval for two imaging products and says the longer-term therapy programs will continue unchanged. But the mysterious episode is not the first time that Telix has slipped up. In April, the FDA knocked back Telix's marketing application for its brain cancer (glioma) diagnostic, telling the company to do more homework. Management said the setback (by way of a Complete Response Letter) was merely temporary and the company would do what Headmaster requested. A year ago, the FDA also rejected the company's filing for its kidney cancer diagnostic Zircaix, on account of an 'unacceptable' manufacturing defect. Telix founder, CEO and head prefect Chris Behrenbruch dubbed the glitches 'relatively minor and fixable'. Indeed, the company re-filed the application and the market awaits an FDA decision by the end of the month. Telix machine is clicking along To date, Telix has derived most of its revenue in the US, from its approved prostate cancer imaging agent Illuccix. Illuccix is a kit for preparing gallium-68 gozetotide – more commonly known as a PSMA-11 injection – for positron emission tomography (PET) scans. Illuccix is used for prostate cancer patients suspected of having either metastasised growths, or a recurrence based on elevated PSA (prostate-specific antigen) levels. Elevated levels in the blood of PSA, a protein, can be a marker of prostate cancer. PSMA (prostate-specific membrane antigen) is a protein found on the surface of prostate cancer cells. Illucix is approved in 17 countries, including the US, the UK, Brazil, Germany, France, Canada and here. In March, the FDA approved second diagnostic, Gozellix (for metastatic castrate resistant prostate cancer). Telix hopes to launch Gozellix in the US in the current quarter. A bit of history Dr Behrenbruch founded Telix in 2015 out of a 'deep frustration' that there was a burgeoning interest in nuclear medicine technologies, but few commercial players. In early 2017 Telix acquired the Dresden-based radio-pharmaceutical outfit Therapeia, founded by Dr Andreas Kluge. Dr Kluge retired from the board in September last year. Telix listed in November 2017, after raising $50 million at 65 cents apiece. In November 2024 the company listed on Nasdaq, having abandoned a $300 million IPO in favour of a $650 million non-US corporate bond issue. Dr Behrenbruch was the executive director of the now defunct Factor Therapeutics and was also on the board of the very un-defunct pancreatic cancer tearaway, Amplia Therapeutics. In 2020, Telix inked a 10-year deal with China Grand Pharmaceutical, worth 'up to' US$225 million from market authorisation. The Hong Kong-based entity became the exclusive partner in greater China for any approved Telix therapy. Telix remains Melbourne based, but most of its commercial activity is in the US. Good golly, it's Gozellix In March this year the FDA approved the company's gallium isotope-based Gozellix, for PET scanning of lesions showing PSMA. While not an expansion to a completely new indication, Gozellix extends the company's US prostate cancer imaging market reach by an estimated 5-10%. Gozellix is for prostate cancer patients with suspected metastasis, who are candidates for initial definitive therapy (prostate removal or broader radiation treatment). It's also for those with suspected recurrence, based on elevated PSA levels. 'The ability to reliably deliver the product much further from its point of production means Gozellix can reach PET cameras that are currently not served by any PSMA imaging providers,' the company says. Gozellix has a longer shelf life of up to six hours, about three times more than Illucix. It can also be used on older scanning machines. On the acquisition trail To expand its repertoire and bolster its manufacturing oomph, Telix has continued an acquisitive splurge. In January Telix acquired a 'proprietary novel biologics technology' from antibody engineering company Imaginab Inc. The platform avails of small, engineered antibody formats that enable specific radiation targeting of cancer. The deal delivers a 'state-of-the-art' research facility in Los Angeles, adding to existing capacity at Sacramento, Angleton (Texas) and across the border in Vancouver. In September 2024 Telix spent $388 million to acquire RLS Radiopharmacies, to expand its North American manufacturing and distribution footprint. RLS derives revenue from providing radiopharmacy products to third party clients. In April, the company bought the Austin-based Isotherapeutics (radio-chemistry services) and the Canadian radio-isotope producer Artms Inc. Let's get clinical It's hard to do justice to Telix's extensive clinical program in a few paragraphs, but here goes … By the end of the year, the company should unveil an initial safety and dosing readout pertaining to its phase III prostate cancer therapy candidate, the lutetium-based TLX-591. The study, Prostact Global, has enrolled 30 men for the part one phase. These patients have PSMA-positive metastatic castrate-resistant prostate cancer. These men are also treated with the standard-of-care chemotherapy drugs, or the standard-of-care alone. To date, TLX-591 has been evaluated in 242 patients across eight phase I/II studies, with 'evidence of anti-tumour effect and a clear dose response profile for key measures of efficacy.' Telix also has mid-stage brain and kidney cancer therapy programs and another one for bone marrow conditioning. Telix also runs earlier stage programs for musculo-skeletal conditions including soft tissue sarcoma, bone metastases and 'pain palliation'. Readers should peruse the company 127-page investor presentation from June 11, but only if they are feeling strong. Finances and performance Telix reported revenue of US$204 million for the June 2025 quarter, up 63% year on year and a 10% increment on the March 2025 quarter. (As of January this year, the company reports in US dollars.) Sales of Illuccix accounted for US$154 million, up 25% year on year. RLS contributed US$46 million of sales, 39% higher than the March quarter. Dr Behrenbruch notes Illuccix dose volumes rose 7%, quarter on quarter. He says despite 'emerging competitive pricing pressure', Telix has 'effective strategies' to maintain average selling prices. Not irrelevantly, Gozellix in July was granted a permanent Healthcare Common Procedure Coding System code. Telix expects to obtain Transitional Pass-Through (TPT) payment status, which provides additional Medicare reimbursement to hospitals using innovative medical devices or drugs. TPT should apply from October 1 with reimbursement of around US$1000 per dose, almost twice that applying to Illuccix. In calendar 2024, Telix expended US$195 million on research and development, up 50%. This year the number should be 20-25% higher again. Telix has maintained calendar 2025 guidance of US$770-800 million, having chalked up first half revenue of US$390 million. We'll know about the innards of Telix's financials at its full-year results on August 21. Over the last 12 months Telix shares have irradiated between $17.44 (early September last year) and a record $31.14 in late January this year. In November 2017 the shares were worth 13 cents. Telix trumps tariffs with US manufacturing Telix says it won't be affected by Trump's drug pricing and tariff proposals. Given Telix's just-in-time products are made in the US out of necessity, they are as American as apple pie and a Colt AR-15 rifle under the bed. 'This will continue to be the case for new products the company expects to launch in 2025,' the company says. As for drug pricing, The Trump administration plans to benchmark certain local therapeutics against those charged in the cheapest of the industrialised nations. Telix reckons it's in the clear because 'localised production makes international pricing comparisons challenging to benchmark'. In any event, the company promises 'pharmaco-economically defensible' pricing. What the brokers say Broking analysts maintain their faith in Telix, despite the distraction of the SEC probe (if we can call it that) and stiffening prostate imaging competition. Broker Jefferies says such SEC entreaties are common, but the issues might take two years or so to resolve. UBS suggests any disclosure shortcomings may relate to Telix's dual ASX/Nasdaq listing, with the company needing to satisfy different requirements across the Pacific. On competition, UBS notes the 7% uptick in Illuccix sales shows Telix is winning market share in a hotter market. The firm believes the launch of Gozellix (and its TPT status) has relieved some of the pricing pressure. UBS values Telix at $36 a share, while Jefferies and Bell Potter plump for a $34 price target. The latter does so on the expectation of FDA approval of Zircaix. UBS says the current valuation assumes 'total scientific and clinical failure' of the therapeutic programs. Valuing the stock at $35, Wilsons says Gozellix provides 'exciting upside' and Telix has 'so many options available to it both competitively and operationally'. The only Grumpy Bob is Morningstar, which in April described Telix as overvalued by about 40%. The research house opined Telix's product pipeline remained 'commercially unproven in an increasingly competitive market'. Dr Boreham's diagnosis Telix faces a pile of homework, but we concur the company can remain dux of the radioimaging class despite the regulatory issues. We should stress that Telix is solidly profitable: UBS plugs in a net profit of $138 million for the 2024-25 year just gone, rising to $480 million within two years. Telix cites a current US prostate cancer imaging market at US$2.5-3.5 billion. But with expanded indications, this figure swells to US$6.7 billion across 1.7 million scans annually. One might think the medical world had nuclear diagnostics down pat by now, but evidently there are isotopes and there are isotopes. In the past, Dr Behrenbruch has described Zircaix as potentially bigger for Telix than Illuccix. Not that he expects the prostate business to slow down. Beyond imaging, if Telix can crack a better therapy for the key cancers in its remit, then its $7 billion market valuation looks only the start. At a glance ASX Code: TLX Share price: $18.53 Shares on issue: 338,399,059 Market cap: $6.27 billion Co-founder and CEO: Dr Christian Behrenbruch Board: Tiffany Olson(chair), Dr Behrenbruch, Dr Mark Nelson, Jann Skinner, Marie McDonald (chairman Kevin McCann retired in May 2025) Financials (June quarter 2025): revenue US$204 million (up 63%) Calendar 2024 year: revenue $783 million (up 56%), adjusted earnings before interest, tax, depreciation and amortisation $99.3 million (up 70%), net profit $49.9 million Major shareholders: Gnosis Verwaltungsgesellschaft (Dr Kluge) 6.88% Elk River Holdings (Dr Behrenbruch) 6.2%, Grand Pharma (China Grand Pharmaceuticals) 3.3%.
AU Financial Review
2 hours ago
- AU Financial Review
ASX set to rise, US stocks edge broadly lower
Australian shares are poised to edge higher. Shares were modestly lower in New York after data on the US services sector disappointed and oil fell after a report Russia is set to propose an air truce with Ukraine. Results expected on Wednesday include AMP, News Corp, REA Group and Pinnacle Investment Management Group. The Institute for Supply Management's index of services declined last month to 50.1, below all estimates in a Bloomberg survey of economists. The employment index contracted. The group's measure of prices paid for materials and services climbed to the highest since October 2022. 'Spending on services has already slowed significantly from its solid pace last year, and the clear deterioration in the labour market and drag on real incomes from tariffs suggest a marked recovery is unlikely,' Pantheon Macroeconomics said. 'Even so, we think stagnation in the coming months is far more likely than a collapse.' President Donald Trump said that Treasury secretary Scott Bessent had withdrawn his name from consideration as a successor to Jerome Powell as chairman of the Federal Reserve. Market highlights ASX futures are pointing up 16 points or 0.2 per cent to 8744. All US prices as near 2.30pm New York time. Today's agenda Results are expected on Wednesday from AMP, News Corp, REA Group, Pinnacle Investment Management Group, BWP Trust, Centuria Industrial Reit, Charter Hall Long WALE REIT and Emerald Resources NL. The data focus is overseas on Wednesday with NZ's second-quarter employment at 8.45am AEST. TD Securities: 'Monthly filled job data imply a negative employment growth print over the quarter at -0.1 per cent. We expect the participation rate to ease again to 70.7 per cent (prior: 70.8) which on net would push the unemployment modestly higher to 5.2 per cent and in line with the RBNZ's May forecast. 'We see the RBNZ cutting by 25bps in August to 3 per cent with most data outcomes coming in line with forecasts but surveys point to near term downside risks to growth.' Top stories Blow to Chalmers' hopes for summit unity as BHP clashes with PC over tax | The nation's biggest corporate taxpayer has pushed back against the Productivity Commission's cash-flow tax proposal, undermining the treasurer's push for unity at his roundtable. Nine's publishing to out-earn free-to-air television in two years | The newspapers division will be the most valuable part of the business after it sells Domain to US property giant CoStar, analysts say. | Automating tasks could deliver a 4.3 per cent increase in labour productivity growth, the Productivity Commission says, but it won't be easy for humans. | The rising cost of building transmission is prompting questions over whether a comprehensive grid build-out is the best energy transition option for consumers.
AU Financial Review
2 hours ago
- AU Financial Review
The PEXA monopoly's stand-in CFO
The monopoly that PEXA enjoys in the e-conveyancing space is near total. Almost everyone who buys and sells real estate in this country pays something like $140 to the ASX-listed, Commonwealth Bank-backed company that sits between banks when the sale goes through. The $340 million in annual fees it collects is, naturally, a red rag to policymakers like ACCC chair Gina Cass-Gottlieb and Assistant Minister for Competition Andrew Leigh. The latter gets so fired up about its singular dominance he starts giving history lessons about Adam Smith.
